Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Mallinckrodt
McKinsey
Colorcon
Harvard Business School
Chinese Patent Office
AstraZeneca
QuintilesIMS

Generated: May 27, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,663,159

« Back to Dashboard

Summary for Patent: 5,663,159
Title: Prodrugs of phosphonates
Abstract:There are disclosed novel oral prodrugs of phosphonate nucleotide analogs which are hydrolyzable under physiological conditions to yield compounds which are useful as antiviral agents, especially as agents effective against RNA and DNA viruses. They may also find use as antitumor agents.
Inventor(s): Starrett, Jr.; John E. (Middletown, CT), Mansuri; Muzammil M. (Cheshire, CT), Martin; John C. (Cheshire, CT), Tortolani; David R. (Meriden, CT), Bronson; Joanne J. (Madison, CT)
Assignee: Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (CZ) N/A (BE) Rega Stichting v.z.w. (
Application Number:08/320,632
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,663,159
Patent Claims: 1. Antivirally active compounds or intermediates therefor of the formula I or V ##STR25## wherein B represents adenyl (A), guanyl (G), or 2,6-diaminopurinyl (DAP);

R.sup.1 and R.sup.2 are independently each OR.sup.4

R.sup.3 represents ##STR26## X represents hydrogen, methyl or hydroxymethyl; R.sup.4 represents a physiologically hydrolyzable group selected from the group consisting of CH.sub.2 OC(O)R.sup.5 and CH(R.sup.5)OC(O)R.sup.5 (R, S, or RS stereochemistry); and

R.sup.5 represents C.sub.1 -C.sub.20 alkyl, aryl or aryl-alkyl which may be substituted or unsubstituted by hydroxy or halogen.

2. Antivirally active compounds or intermediates therefor of Formula III ##STR27## wherein B represents adenyl (A), guanyl (G), or diaminopurinyl (DAP); R.sup.7 is OH;

X represents hydrogen, methyl or hydroxymethyl;

R.sup.1 is OR.sup.4 ;

R.sup.4 represents a physiologically hydrolyzable group selected from the group consisting of CH.sub.2 OC(O)R.sup.5 and CH(R.sup.5)OC(O)R.sup.5 (R, S, or RS stereochemistry); and

R.sup.5 represents C.sub.1 -C.sub.20 alkyl, aryl or aryl-alkyl which may be substituted or unsubstituted by hydroxy or halogen.

3. The compound of claim 1 wherein X is H and R.sup.5 is C.sub.1 -C.sub.20 alkyl.

4. The compound of claim 2 wherein X is H or hydroxymethyl.

5. The compound of claim 1 wherein X is H.

6. The compound of claim 1 wherein X is hydroxymethyl or methyl.

7. The compound of claim 1 wherein B is adenyl.

8. The compound of claim 7 wherein X is H and R.sup.4 is CH.sub.2 OC(O)R.sup.5.

9. The compound of claim 1 which is 9-(2-phosphonylmethoxy) ethyladenine di(pivaloyloxymethyl)ester.

10. The compound of claim 1 which is 9-(2-phosphonylmethoxy) ethyladenine di(propionyloxymethyl)ester.

11. The compound of claim 1 which is 9-(2-phosphonylmethoxy) ethyladenine di(isobutyryloxymethyl)ester.

12. The compound of claim 1 which is 9-(2-phosphonylmethoxy) ethyladenine di(benzoyloxymethyl)ester.

13. A composition comprising the compound of claim 1 in association with a pharmaceutically acceptable substantially nontoxic carrier or excipient.

14. The compound of claim 2 wherein X is H.

15. The compound of claim 2 wherein X is hydroxymethyl or methyl.

16. The compound of claim 2 wherein R.sup.4 is CH.sub.2 OC(O)R.sup.5.

17. The compound of claim 2 which is 9-(2-phosphonylmethoxy) ethyladenine mono(pivaloyloxymethyl)ester.

18. A method for the treatment of HSV-2, HCMV or HIV in a mammal which comprises orally administering to the mammal an antiviral effective non-toxic dose of 9-(2-phosphonylmethoxy) ethyladenine di(pivaloyloxymethyl)ester for a treatment period of sufficient duration to mitigate said infection.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
QuintilesIMS
Harvard Business School
Merck
Covington
Chubb
Cipla
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.